gastric cancer

News

Amgen's Five Prime takeover delivers gastric cancer win

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.

Oncology

ASCO 2025: Building a stronger future in cancer care with a ...

From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the

News

ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

News

Astellas adds to claudin clout with $1.3bn+ Evopoint deal

Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline.

News

Enhertu extends survival in advanced gastric cancer

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.

News

CARsgen gets a win for CAR-T in solid tumours

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

Amgen's Five Prime takeover delivers gastric cancer win

ASCO 2025: Building a stronger future in cancer care with a ...

ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer

Astellas adds to claudin clout with $1.3bn+ Evopoint deal

Enhertu extends survival in advanced gastric cancer

CARsgen gets a win for CAR-T in solid tumours

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

gastric cancer

Editor's Picks